Back to articles

The Rare Few Stocks to Buy in May

The “sell in May and go away” headlines are right around the corner.

And who can blame the media machine for using them? It’s one of few folksy market mantras with historical merit. Stock returns from May to October are traditionally poor compared to the November-to-April period.

But I asked myself: Can that be true of every single stock? Surely not…

Today, in a special video analysis with contributing editor Lucas Downey, we answer the question of what stocks are actually worth buying even through the traditionally bearish period that’s fast approaching.

The answer may surprise you… And give you a great bundle of high-quality names for your watchlist.

And what’s more, we check in on our November call to get bullish… and take stock of what impact major geopolitical events – like what’s happening in the Middle East – actually have on the stock market.

Related content

Cannabis Stocks are a Gateway Drug to Losses (For Now Anyway)

November 19, 2019TradeSmith Research Team

Cannabis investors have a message for Joe Biden: The 1990s called, they want their worldview back. Biden, a U.S. presidential candidate and front runner among Democrats, hurt pot stocks this week by expressing the view that marijuana is a “gateway drug” and shouldn’t be legalized for that reason. The irritated response from cannabis investors and marijuana enthusiasts — and even from a handful of politicians on both sides of the aisle — was to point out that the “gateway drug”

The Babe Ruth and Joe DiMaggio of Money Managers is Constructively Bullish

January 2, 2020TradeSmith Research Team

There are very few money managers (let alone retired ones) who are always worth listening to. Stanley Druckenmiller is one of them. Because of his track record — 30% average compound returns over 30-plus years, with no losing years — Druckenmiller is like Babe Ruth and Joe DiMaggio combined. What’s more, Druckenmiller earned his incredible track record managing many billions of dollars rather than small sums. (It is normally much harder to book stellar returns on a large asset base.)